Patents by Inventor Mark J. Litton

Mark J. Litton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
    Patent number: 9546213
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: January 17, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
  • ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER
    Publication number: 20110217303
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: March 14, 2011
    Publication date: September 8, 2011
    Inventors: Jeffrey T.L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
  • Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
    Patent number: 7906117
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: March 15, 2011
    Assignee: AlderBio Holdings LLC
    Inventors: Jeffrey T. L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham
  • Antagonists of IL-6 to prevent or treat Cachexia, weakness, fatigue, and/or fever
    Publication number: 20090291077
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: November 25, 2008
    Publication date: November 26, 2009
    Inventors: Jeffrey T.L. Smith, Randall C. Schatzman, Mark J. Litton, John Latham